Herbert L. Fred, MD,

Editor, Correspondence Section

Circulation Editorial Office.

St Luke's Episcopal Hospital/Texas Heart Institute

6720 Bertner Avenue

Room B524 (MC1-267)

Houston, TX 77030-2697

 

Letter to the Editor: Clopidogrel in Acute Coronary Syndromes. Can the cost-effectiveness improve?.

Accepted for publication: April 2, 2003 by Herbert L. Fred, MD, Editor, Correspondence Section, and James T. Willerson, MD, Editor-In-Chief , CIRCULATION.

 

The usefulness of clopidogrel  and aspirin  in acute coronary syndromes (CURE trial) was clear from the beginning, and confirmed again in the new report from Salim Yusuf et. al. (1). The actual question is: could the cost-effectiveness still be improved?.

 

I propose the combination of Aspirin and Clopidogrel during the first 30 days. Beyond 30 days, these medications could be given on alternate days, one day Aspirin and the other day Clopidogrel. That would reduce the cost, probably not affecting the efficacy and maybe reducing the risk of life-threatening bleeds.

 

With this approach, the main effect is reached in the first 30 days (4.3% vs. 5.4%), when one needs to treat 91 patients to prevent one event. Beyond 30 days, the events rise only 0.9% in total (5.2% vs. 6.3%), the relative risk reduction remains 18%, and the absolute risk reduction is then only 0.16%, resulting in a Number Needed to Treat of 625 to prevent an event. It is also important to remember that the effect of Aspirin is irreversible, so that it is active on the day off, and the new, not affected platelets, would be then inhibited by Clopidogrel.

 

This strategy could be very useful for the patients (and doctors) with limited economic resources. These approach could also be useful in cases of resistance to Aspirin.

 

Enrique Sánchez-Delgado, MD

Medical Director

Hospital Metropolitano

Managua, Nicaragua

 

1.- Yusuf S, Mehta SR, Zhao F et al. Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes. Circulation 2003 107: 966 – 972.

 

Dear Dr. Sanchez-Delgado,

You raise an important issue and I hope Circulation will publish your paper.

Kind regards,

Salim Yusuf, D.Phil, FRCPC
Professor of Medicine
Director, Division of Cardiology
Director, Population Health Research Institute
McMaster University

Thu, 6 Mar 2003 12:17:22 -0500